SCHEMBL5537632

SCHEMBL5537632

[c]1ccc(-c2ccoc2)cn1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
PPARA Q07869 1/20 0.32
ERN1 O75460 2/20 0.32
NPBWR1 P48145 1/20 0.31
NT5E P21589 1/20 0.31
FYN P06241 1/20 0.31
ALDH1A1 P00352 4/20 0.30
CYP1A2 P05177 4/20 0.30
CYP2D6 P10635 4/20 0.30
CYP3A4 P08684 3/20 0.30
CYP2C19 P33261 3/20 0.30
HSD17B10 Q99714 3/20 0.30
CLK4 Q9HAZ1 3/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
ALOX15 P16050 2/20 0.30
USP2 O75604 1/20 0.30
TSHR P16473 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7191487 0.72 LPL (0.46) LPLLIPGERN1ALDH1A1CYP1A2
SCHEMBL196321 0.72 LPL (0.41) LPLLIPGERN1NPBWR1ALDH1A1
SCHEMBL69790 0.70 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP3A4HSD17B10MEN1
SCHEMBL17701218 0.69 HDAC4 (0.38)
SCHEMBL971910 0.69 CYP11B1 (0.38) PPARAFYNALDH1A1CYP1A2CYP2D6
SCHEMBL28309472 0.69
SCHEMBL746460 0.68 CYP2A6 (0.46) ERN1ALDH1A1CYP1A2CYP3A4
SCHEMBL14438064 0.68 HPGDS (0.42) LPLLIPGPPARAERN1NT5E
SCHEMBL1772039 0.67 LPL (0.54) LPLLIPGERN1NPBWR1ALDH1A1
SCHEMBL4781095 0.67 AHR (0.41) CYP1A2MEN1KMT2ATSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LPL 4818/4885LIPG 4880/4885PPARA 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.